Reports Q4 revenue $19.4M vs $17.5M last year. “We are proud to close out 2024 with another record-breaking quarter, marking our fourteenth ...

IRadimed Corporation achieves record Q4 2024 revenue, driven by IV pump demand and monitor sales focus. Learn about their growth strategy & 2025 outlook.

Reducing intravenous (IV) isatuximab delivery from 75 minutes to 30 minutes could provide a wealth of benefits to patients ...

The US Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in ...